

# IN VITRO TOXICITY TESTING: TECHNOLOGIES AND GLOBAL MARKETS



PHM017E  
January 2014

Robert Hunter  
*Project Analyst*

ISBN: 1-56965-661-4

**bcc** | Research  
Market Forecasting

**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481 USA  
866-285-7215 (toll-free within the USA),  
or (+1) 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
[information@bccresearch.com](mailto:information@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	3
STUDY GOALS AND OBJECTIVES	3
REASONS FOR DOING THE STUDY	3
SCOPE OF REPORT	3
INTENDED AUDIENCE	4
METHODOLOGY AND INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	4
RELATED REPORTS	5
BCC RESEARCH ONLINE SERVICES	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE TOTAL GLOBAL MARKET FOR PREDICTIVE TOXICOLOGY, THROUGH 2017 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE TOTAL GLOBAL MARKET FOR PREDICTIVE TOXICOLOGY, 2011-2017 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW	11
BASICS OF TOXICOLOGY	11
TYPES AND APPLICATIONS	11
REGULATORY RISK ASSESSMENT	12
PRODUCT TOXICITY TESTS	12
DEGREES OF TOXICITY	13
ABOUT DOSES	14
DOSE	14
DOSE RESPONSE	14
THRESHOLD DOSE	14
ABOUT TOXIC SUBSTANCES	14
TOXICANT	14
TOXIN	15
ACUTE AND CHRONIC TOXICITY	15
TOXICOKINETICS	15
ABSORPTION	15
Oral	15
Inhalation	16
Dermal and Parenteral Routes	16
DISTRIBUTION	16
METABOLISM	16
EXCRETION	17
TRADITIONAL (IN VIVO) TOXICOLOGY	17
ISSUES WITH IN VIVO APPROACHES	17
Reduction, Refinement and Replacement - the '3Rs' Driver	17
Other Drivers	18
Background: Sheer Volume of Testing Required	18
Conflicting Data	18
Megadosing	19

<b>TOPIC</b>	<b>PAGE NO.</b>
Time and Cost	19
Mixtures of Chemicals	19
Example of Endocrine-Disrupting Chemicals: Bisphenol A	19
NEED FOR MORE EXPOSURE SCIENCE	20
EVOLUTION OF IN VITRO METHODS	21
TOXCAST	21
TOX 21	22
REACH	22
EU RESEARCH FRAMEWORKS	22
CURRENT ADOPTION OF IN VITRO METHODS	23
INDUSTRY STRUCTURE	23
EXAMPLE OF COMMERCIAL ADOPTION: CARDIOVASCULAR TESTING	25
CHAPTER 4 SPECIFIC TOXICITY TESTS AND FOUNDATIONAL SOLUTIONS (SMALLER SCALE)	27
TESTING FOR ADVERSE EFFECTS ON THE SKIN	27
SKIN IRRITATION	27
SKIN CORROSION	28
PHOTOTOXICITY	29
SKIN SENSITIZATION	29
TESTING FOR EYE IRRITATION	30
OVERVIEW OF ACUTE SYSTEMIC TOXICITY	31
TESTING FOR ACUTE TOXICITY	31
<i>TABLE 1 APPROXIMATE RAT ORAL LD50 FOR VARIOUS CHEMICAL SUBSTANCES (MG/KG)</i>	32
USE OF CYTOTOXICITY ASSAYS FOR ACUTE TOXICITY TESTING	33
EXAMPLE OF COMMERCIALY AVAILABLE CYTOTOXICITY ASSAY KIT	34
CHRONIC/REPEATED DOSE TOXICITY	34
GOALS OF CHRONIC/REPEATED DOSE TOXICITY STUDIES	35
Effects of Accumulation and Frequency of Exposure	35
Dosage Levels	36
Duration	36
Reversibility	36
Analysis	37
Development of Repeated Dose Toxicity Testing In Vitro	37
CARCINOGENICITY AND GENOTOXICITY	37
INTRODUCTION	37
IN VITRO METHODS: BACKGROUND AND RECENT DEVELOPMENTS	37
REGULATORY VERSUS DRUG DEVELOPMENT APPLICATIONS	38
THE AMES TEST	38
IN VITRO MICRONUCLEUS TEST (MNT)	39
EFFORTS TO REDUCE FALSE POSITIVES	39
EXAMPLE OF RECENT INNOVATIONS	39
FUTURE CHALLENGE: NONGENOTOXIC CARCINOGENS	40
REPRODUCTIVE AND DEVELOPMENTAL TOXICITY	41
BACKGROUND	41
FOLLOWING THE REPRODUCTIVE CYCLE	41
Embryotoxicity	42

<b>TOPIC</b>	<b>PAGE NO.</b>
FEMALE REPRODUCTIVE TOXICITY	42
MALE REPRODUCTIVE TOXICITY	42
TYPES OF REPRODUCTIVE AND DEVELOPMENT TESTING	43
Zebrafish Model for Developmental Toxicity Screening	43
Combinations of Zebrafish and Stem Cells	44
BIOMEDICAL FRONTIERS	44
ENDOCRINE DISRUPTOR SCREENING	45
BACKGROUND	45
ENVIRONMENTAL TOXICOLOGY IMPACTS ON IN VITRO METHODS	45
U.S. EPA ENDOCRINE DISRUPTOR SCREENING PROGRAM	46
<i>TABLE 2 ASSAYS INCLUDED IN THE TIER 1 SCREENING BATTERY, IN VITRO AND IN VIVO</i>	46
HIGH PRODUCTION VOLUME (HPV) CHEMICALS	47
EDSP 21 Initiative	47
Future Challenge: Thyroid Disruption	47
EXAMPLE OF RECENT DEVELOPMENT: 'BG1' ASSAY	47
CHALLENGE FOR CHEMICAL COMPANIES: DEPTH AND BREADTH	48
Example of a Resource with Full Depth and Breadth	48
TOXICOKINETICS	49
IN VITRO DEVELOPMENTS	50
METABOLISM	50
In Vitro Metabolism Offerings	51
Metabolism Reaction Phenotyping for Genetic Polymorphisms	51
DEVELOPMENTS IN ABSORPTION BARRIER MODELS	52
Gastrointestinal	52
Lung	52
Blood-Brain Barrier	53
REVENUE ESTIMATE	54
SUMMARY	54
<i>TABLE 3 FORECAST FOR FOUNDATIONAL PRODUCTS AND SERVICES USED IN PREDICTIVE TOXICOLOGY, THROUGH 2017 (\$ MILLIONS)</i>	54
REVENUE ESTIMATE DETAILS AND PARTIAL LISTS OF SUPPLIERS	54
Tissues, Cell Lines, Primary Cells, Stem Cells	54
<i>TABLE 4 EXAMPLES OF TISSUE-BASED PRODUCTS USED IN PREDICTIVE TOXICOLOGY</i>	55
<i>TABLE 5 EXAMPLES OF ORGANIZATIONS OFFERING IMMORTALIZED CELL LINES USED IN PREDICTIVE TOXICOLOGY</i>	55
<i>TABLE 6 EXAMPLES OF COMPANIES OFFERING PRIMARY CELLS FOR PREDICTIVE TOXICOLOGY</i>	56
<i>TABLE 7 EXAMPLES OF COMPANIES PROVIDING STEM CELLS FOR PREDICTIVE TOXICOLOGY</i>	56
REAGENTS AND LABWARE	57
<i>TABLE 8 EXAMPLES OF COMPANIES OFFERING REAGENTS AND LABWARE FOR PREDICTIVE TOXICOLOGY</i>	57
Services	57
<i>TABLE 9 EXAMPLES OF COMPANIES OFFERING SERVICES TAILORED FOR PREDICTIVE TOXICOLOGY</i>	58
Basic Equipment	58

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 10 EXAMPLES OF COMPANIES SUPPLYING BASIC EQUIPMENT FOR FOUNDATIONAL TOXICOLOGY</i>	59
INDUSTRY SEGMENTATION	59
COSMETICS INDUSTRY	59
<i>TABLE 11 FOUNDATIONAL TOXICOLOGY REVENUES ATTRIBUTED TO COSMETICS INDUSTRY, THROUGH 2017 (\$ MILLIONS)</i>	60
PHARMACEUTICAL INDUSTRY	61
<i>TABLE 12 FOUNDATIONAL TOXICOLOGY REVENUES ATTRIBUTED TO PHARMACEUTICAL INDUSTRY, THROUGH 2017 (\$ MILLIONS)</i>	61
CHEMICAL INDUSTRY	62
<i>TABLE 13 FOUNDATIONAL TOXICOLOGY REVENUES ATTRIBUTED TO CHEMICAL INDUSTRY, THROUGH 2017 (\$ MILLIONS)</i>	62
CHAPTER 5 TOOLS USED FOR TRANSCRIPTOMICS, PROTEOMICS AND METABOLOMICS	64
OVERVIEW	64
OVERVIEW OF TRANSCRIPTOMICS	64
TOOLS USED IN TRANSCRIPTOMICS	65
MICROARRAYS	65
NEXT-GENERATION SEQUENCING	66
OVERVIEW OF PROTEOMICS	66
OVERVIEW OF METABOLOMICS	67
OVERVIEW OF METALLOMICS	68
TOOLS USED IN PROTEOMICS	68
<i>TABLE 14 PARTIAL LIST OF MASS SPEC SYSTEMS FOCUSED ON PROTEOMICS APPLICATIONS</i>	69
TOOLS USED IN METABOLOMICS	70
DETECTION	70
SEPARATION	71
HYPHENATED APPROACHES	71
<i>TABLE 15 COMMON ANALYTICAL PLATFORMS USED IN METABOLOMICS</i>	72
TOOLS USED IN METALLOMICS	73
REVENUE ESTIMATE FOR TRANSCRIPTOMICS TOOLS	73
<i>TABLE 16 GLOBAL MARKET FOR TRANSCRIPTOMICS TOOLS USED IN PREDICTIVE TOXICOLOGY, THROUGH 2017 (\$ MILLIONS)</i>	73
TOOLS USED IN PROTEOMICS AND METABOLOMICS	73
DETECTION - USED IN PROTEOMICS AND METABOLOMICS	74
<i>TABLE 17 GLOBAL MASS SPECTROMETRY MARKET, THROUGH 2017 (\$ BILLIONS)</i>	74
SEPARATION - USED IN METABOLOMICS	74
REVENUE ESTIMATE FOR PROTEOMICS AND METABOLOMICS TOOLS	75
<i>TABLE 18 GLOBAL MARKET FOR PROTEOMICS AND METABOLOMICS TOOLS USED IN PREDICTIVE TOXICOLOGY, THROUGH 2017 (\$ MILLIONS)</i>	75
DISCUSSION	75
CHAPTER 6 CELLOMICS	78
BACKGROUND	78
EARLIER APPLICATIONS OF FLUORESCENCE	78
HIGH CONTENT SCREENING (HCS)	79

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 19 EXAMPLES OF COMPANIES SUPPLYING HIGH CONTENT SCREENING (HCS) SOLUTIONS FOR PREDICTIVE TOXICOLOGY</i>	81
LABEL-FREE PLATFORMS	81
<i>TABLE 20 EXAMPLES OF LABEL-FREE TECHNOLOGY AND THE COMPANIES SUPPLYING THEM</i>	82
ELECTROPHYSIOLOGY	82
<i>TABLE 21 EXAMPLES OF COMPANIES PROVIDING SERVICES FOCUSED ON CELLOMICS (LARGER SCALE STUDIES) FOR PREDICTIVE TOXICOLOGY</i>	83
RECAP OF PREDICTIVE VS. MECHANISTIC	83
SAFETY TESTING OF CARDIOVASCULAR DRUG CANDIDATES	84
MICROELECTRODE ARRAYS (MEA) BASED ON IMPEDANCE	84
MICROARRAY TECHNOLOGY USED IN CELLOMICS	85
REVENUE ESTIMATE	86
<i>TABLE 22 ESTIMATED REVENUES FOR CELLOMICS TOOLS USED IN PREDICTIVE TOXICOLOGY BY TYPE OF EQUIPMENT, THROUGH 2017 (\$ MILLIONS)</i>	87
CHAPTER 7 ASSAY KITS, CELL LINES, STEM CELLS, CONSUMABLES AND SERVICES FOR LARGER SCREENING APPLICATIONS	89
OVERVIEW	89
REAGENTS FOR 'HOMEBREW' ASSAY DEVELOPMENT	89
ASSAY KITS FOR HIGH CONTENT SCREENING	89
CELL-BASED ASSAYS: OVERVIEW AND NEWER DEVELOPMENTS	89
COMPONENTS OF CELL-BASED ASSAY SYSTEMS	90
Microplates	91
IMPORTANCE OF 3D VERSUS 2D SYSTEMS	92
Microfluidics and 'Organs on a Chip'	93
3D Models for Skin	93
TYPES OF CELLS USED IN CELL-BASED ASSAYS	93
Immortalized Cell Lines and Primary Cells for Screening	94
Stem Cells at Scale for Screening	94
MODEL FOR ADOPTION: CARDIOVASCULAR SAFETY TESTING	95
APPLICATIONS IN LIVER TOXICITY STUDIES	97
USE OF STEM CELL-DERIVED HEPATOCYTES	98
CURRENT CHALLENGES: APPLICATIONS TO IMMUNE MEDIATED DILI	98
APPLICATIONS IN KIDNEY TOXICITY STUDIES	99
FUTURE CHALLENGE: STEM-CELL DERIVED KIDNEY CELLS	100
REVENUE FORECAST	100
<i>TABLE 23 ESTIMATED REVENUES FOR ASSAY KITS, OTHER CONSUMABLES AND ASSOCIATED SERVICES USED IN PREDICTIVE TOXICOLOGY BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	100
CHAPTER 8 OVERVIEW OF IN SILICO TOOLS USED IN PREDICTIVE TOXICOLOGY	102
BACKGROUND	102
GENE EXPRESSION CLASSIFIERS BASED ON STATISTICAL ANALYSIS	102
FUNCTIONAL CLASSIFIERS BASED ON PATHWAYS AND NETWORKS	103
USE OF PATHWAY MAPS	104
QSARS	106
MODEL-BASED DRUG DEVELOPMENT	106
EXAMPLES OF COMMERCIALY AVAILABLE SOLUTIONS	107

<b>TOPIC</b>	<b>PAGE NO.</b>
INGENUITY PATHWAY ANALYSIS (IPA)	107
GENEDATA SCREENER AND EXPRESSIONIST	109
THOMSON REUTERS METADRUG	109
ENTELOS PHYSIOLAB MODELER	110
REVENUE ESTIMATE	110
<i>TABLE 24 ESTIMATED REVENUES FOR IN SILICO PRODUCTS AND ASSOCIATED SERVICES USED IN PREDICTIVE TOXICOLOGY, BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	110
CHAPTER 9 BIOMARKERS AND OTHER BREAKOUT BUSINESS MODELS	112
BIOMARKERS	112
OVERVIEW AND SCOPE	112
CHALLENGES AND POSSIBLE SOLUTIONS	113
DRUG RESCUE	114
PRECISION MEDICINE APPLICATIONS	114
REVENUE ESTIMATE	115
<i>TABLE 25 ESTIMATED REVENUES FOR BIOMARKERS AND OTHER BREAKOUT BUSINESS MODELS BASED ON PREDICTIVE TOXICOLOGY BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	115
CHAPTER 10 APPENDIX	117
PATENT ANALYSIS	117
<i>TABLE 26 EXAMPLES OF SOME IMPORTANT PATENTS RELATIVE TO PREDICTIVE TOXICOLOGY</i>	117
SAMPLE COMPANY PROFILES	121
ACCELRY'S INC.	121
ACEA BIOSCIENCES INC.	122
AGILENT TECHNOLOGIES INC.	123
APTUIT INC.	125
BIOGNOSYS AG	126
BIORELIANCE	128
CEETOX INC.	129
CELLULAR DYNAMICS INTERNATIONAL INC.	130
CENTER FOR ALTERNATIVES TO ANIMAL TESTING (CAAT)	131
CHANTEST	132
CHARLES RIVER LABORATORIES	133
CYPROTEX PLC	134
ENTELOS	135
ENZO LIFE SCIENCES INC.	136
EUROPEAN UNION REFERENCE LABORATORY FOR ALTERNATIVES TO ANIMAL TESTING (EURL)	138
GE HEALTHCARE LIFE SCIENCES UK	138
GENEDATA	140
GENTRONIX LIMITED	140
THE HAMNER INSTITUTES FOR HEALTH SCIENCES	141
HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE (HESI)	142
HUMANE SOCIETY INTERNATIONAL (HSI)	143
HUREL CORPORATION	144
IMSTAR S.A.	145

<b>TOPIC</b>	<b>PAGE NO.</b>
INGENUITY SYSTEMS	146
INSPHERO AG	147
INSTITUTE FOR IN VITRO SCIENCES INC. (IIVS)	148
INTELLICYT CORPORATION	149
KIYATEC INC.	150
MEDICYTE GMBH	151
METABOLON INC.	152
MOLECULAR DEVICES, LLC	153
NTP INTERAGENCY CENTER FOR THE EVALUATION OF ALTERNATIVE TOXICOLOGICAL METHODS (NICEATM)	155
OCIMUM BIOSOLUTIONS LCC	156
PERKINELMER INC.	157
STEMINA BIOMARKER DISCOVERY INC.	158
STRATATECH CORPORATION	159
SYNVIVO INC.	160
THERMO FISHER SCIENTIFIC	161
TNO	162
VALA SCIENCES INC.	163
VISTAGEN THERAPEUTICS INC.	164
ZEN-BIO INC.	165
XRPRO CORPORATION	165



**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE TOTAL GLOBAL MARKET FOR PREDICTIVE TOXICOLOGY, THROUGH 2017 (\$ MILLIONS)	6
TABLE 1 APPROXIMATE RAT ORAL LD50 FOR VARIOUS CHEMICAL SUBSTANCES (MG/KG)	31
TABLE 2 ASSAYS INCLUDED IN THE TIER 1 SCREENING BATTERY, IN VITRO AND IN VIVO	45
TABLE 3 FORECAST FOR FOUNDATIONAL PRODUCTS AND SERVICES USED IN PREDICTIVE TOXICOLOGY, THROUGH 2017 (\$ MILLIONS)	53
TABLE 4 EXAMPLES OF TISSUE-BASED PRODUCTS USED IN PREDICTIVE TOXICOLOGY	54
TABLE 5 EXAMPLES OF ORGANIZATIONS OFFERING IMMORTALIZED CELL LINES USED IN PREDICTIVE TOXICOLOGY	54
TABLE 6 EXAMPLES OF COMPANIES OFFERING PRIMARY CELLS FOR PREDICTIVE TOXICOLOGY	55
TABLE 7 EXAMPLES OF COMPANIES PROVIDING STEM CELLS FOR PREDICTIVE TOXICOLOGY	55
TABLE 8 EXAMPLES OF COMPANIES OFFERING REAGENTS AND LABWARE FOR PREDICTIVE TOXICOLOGY	56
TABLE 9 EXAMPLES OF COMPANIES OFFERING SERVICES TAILORED FOR PREDICTIVE TOXICOLOGY	57
TABLE 10 EXAMPLES OF COMPANIES SUPPLYING BASIC EQUIPMENT FOR FOUNDATIONAL TOXICOLOGY	58
TABLE 11 FOUNDATIONAL TOXICOLOGY REVENUES ATTRIBUTED TO COSMETICS INDUSTRY, THROUGH 2017 (\$ MILLIONS)	59
TABLE 12 FOUNDATIONAL TOXICOLOGY REVENUES ATTRIBUTED TO PHARMACEUTICAL INDUSTRY, THROUGH 2017 (\$ MILLIONS)	60
TABLE 13 FOUNDATIONAL TOXICOLOGY REVENUES ATTRIBUTED TO CHEMICAL INDUSTRY, THROUGH 2017 (\$ MILLIONS)	61
TABLE 14 PARTIAL LIST OF MASS SPEC SYSTEMS FOCUSED ON PROTEOMICS APPLICATIONS	68
TABLE 15 COMMON ANALYTICAL PLATFORMS USED IN METABOLOMICS	71
TABLE 16 GLOBAL MARKET FOR TRANSCRIPTOMICS TOOLS USED IN PREDICTIVE TOXICOLOGY, THROUGH 2017 (\$ MILLIONS)	72
TABLE 17 GLOBAL MASS SPECTROMETRY MARKET, THROUGH 2017 (\$ BILLIONS)	73
TABLE 18 GLOBAL MARKET FOR PROTEOMICS AND METABOLOMICS TOOLS USED IN PREDICTIVE TOXICOLOGY, THROUGH 2017 (\$ MILLIONS)	74
TABLE 19 EXAMPLES OF COMPANIES SUPPLYING HIGH CONTENT SCREENING (HCS) SOLUTIONS FOR PREDICTIVE TOXICOLOGY	80
TABLE 20 EXAMPLES OF LABEL-FREE TECHNOLOGY AND THE COMPANIES SUPPLYING THEM	81
TABLE 21 EXAMPLES OF COMPANIES PROVIDING SERVICES FOCUSED ON CELLOMICS (LARGER SCALE STUDIES) FOR PREDICTIVE TOXICOLOGY	82
TABLE 22 ESTIMATED REVENUES FOR CELLOMICS TOOLS USED IN PREDICTIVE TOXICOLOGY BY TYPE OF EQUIPMENT, THROUGH 2017 (\$ MILLIONS)	86
TABLE 23 ESTIMATED REVENUES FOR ASSAY KITS, OTHER CONSUMABLES AND ASSOCIATED SERVICES USED IN PREDICTIVE TOXICOLOGY BY TYPE, THROUGH 2017 (\$ MILLIONS)	99
TABLE 24 ESTIMATED REVENUES FOR IN SILICO PRODUCTS AND ASSOCIATED SERVICES USED IN PREDICTIVE TOXICOLOGY, BY TYPE, THROUGH 2017 (\$ MILLIONS)	109
TABLE 25 ESTIMATED REVENUES FOR BIOMARKERS AND OTHER BREAKOUT BUSINESS MODELS BASED ON PREDICTIVE TOXICOLOGY BY TYPE, THROUGH 2017 (\$ MILLIONS)	114

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 26 EXAMPLES OF SOME IMPORTANT PATENTS RELATIVE TO PREDICTIVE TOXICOLOGY	116

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE TOTAL GLOBAL MARKET FOR PREDICTIVE TOXICOLOGY, 2011-2017 (\$ MILLIONS)	6